Global Irritable Bowel Syndrome (IBS) Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2024

  • receipt Report ID : 156686
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 119
  • list Pharmaceuticals and Healthcare

IBS is a chronic disorder characterized by abdominal pain or discomfort associated with altered bowel function for at least three months, according to the Rome III criteria. Patients often experience relapse of symptoms over time.

Scope of the Report:

This report focuses on the Irritable Bowel Syndrome (IBS) Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Irritable Bowel Syndrome (IBS) Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Abbott Laboratories

Synergy Pharmaceuticals

Sucampo Pharmaceuticals

Valeant Pharmaceuticals International

Ardelyx

Astellas Pharma

Novartis

GlaxoSmithKline

Ironwood Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Blautix (Strain)

Bekinda (IBS-D)

SYN-010

Tenapanor

Market Segment by Applications, can be divided into

Hospital

Research

There are 15 Chapters to deeply display the global Irritable Bowel Syndrome (IBS) Therapeutics market.

Chapter 1, to describe Irritable Bowel Syndrome (IBS) Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Irritable Bowel Syndrome (IBS) Therapeutics, with sales, revenue, and price of Irritable Bowel Syndrome (IBS) Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Irritable Bowel Syndrome (IBS) Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Irritable Bowel Syndrome (IBS) Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Irritable Bowel Syndrome (IBS) Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Irritable Bowel Syndrome (IBS) Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Blautix (Strain)

1.2.2 Bekinda (IBS-D)

1.2.3 SYN-010

1.2.4 Tenapanor

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Research

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Abbott Laboratories

2.1.1 Business Overview

2.1.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Abbott Laboratories Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Synergy Pharmaceuticals

2.2.1 Business Overview

2.2.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Synergy Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Sucampo Pharmaceuticals

2.3.1 Business Overview

2.3.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Sucampo Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Valeant Pharmaceuticals International

2.4.1 Business Overview

2.4.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Valeant Pharmaceuticals International Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Ardelyx

2.5.1 Business Overview

2.5.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Ardelyx Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Astellas Pharma

2.6.1 Business Overview

2.6.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Astellas Pharma Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Novartis

2.7.1 Business Overview

2.7.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Novartis Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 GlaxoSmithKline

2.8.1 Business Overview

2.8.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 GlaxoSmithKline Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 Ironwood Pharmaceuticals

2.9.1 Business Overview

2.9.2 Irritable Bowel Syndrome (IBS) Therapeutics Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Ironwood Pharmaceuticals Irritable Bowel Syndrome (IBS) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturer Market Share in 2017

3.3.2 Top 6 Irritable Bowel Syndrome (IBS) Therapeutics Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Analysis by Regions

4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Regions (2013-2018)

4.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Regions (2013-2018)

4.2 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

4.3 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

4.5 South America Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

5 North America Irritable Bowel Syndrome (IBS) Therapeutics by Countries

5.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Countries (2013-2018)

5.1.2 North America Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Countries (2013-2018)

5.2 United States Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

5.3 Canada Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

5.4 Mexico Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

6 Europe Irritable Bowel Syndrome (IBS) Therapeutics by Countries

6.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Countries (2013-2018)

6.2 Germany Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

6.3 UK Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

6.4 France Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

6.5 Russia Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

6.6 Italy Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

7 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics by Countries

7.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Countries (2013-2018)

7.2 China Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

7.3 Japan Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

7.4 Korea Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

7.5 India Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

8 South America Irritable Bowel Syndrome (IBS) Therapeutics by Countries

8.1 South America Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Countries (2013-2018)

8.1.2 South America Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

8.3 Argentina Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

8.4 Colombia Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

9 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics by Countries

9.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

9.3 UAE Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

9.4 Egypt Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

9.5 Nigeria Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

9.6 South Africa Irritable Bowel Syndrome (IBS) Therapeutics Sales and Growth Rate (2013-2018)

10 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Segment by Type

10.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Blautix (Strain) Sales Growth and Price

10.2.1 Global Blautix (Strain) Sales Growth (2013-2018)

10.2.2 Global Blautix (Strain) Price (2013-2018)

10.3 Bekinda (IBS-D) Sales Growth and Price

10.3.1 Global Bekinda (IBS-D) Sales Growth (2013-2018)

10.3.2 Global Bekinda (IBS-D) Price (2013-2018)

10.4 SYN-010 Sales Growth and Price

10.4.1 Global SYN-010 Sales Growth (2013-2018)

10.4.2 Global SYN-010 Price (2013-2018)

10.5 Tenapanor Sales Growth and Price

10.5.1 Global Tenapanor Sales Growth (2013-2018)

10.5.2 Global Tenapanor Price (2013-2018)

11 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Segment by Application

11.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Research Sales Growth (2013-2018)

12 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.2.2 Europe Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.2.4 South America Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast (2018-2023)

12.3 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Share Forecast by Type (2018-2023)

12.4 Irritable Bowel Syndrome (IBS) Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global Irritable Bowel Syndrome (IBS) Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global Irritable Bowel Syndrome (IBS) Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Irritable Bowel Syndrome (IBS) Therapeutics Picture

Table Product Specifications of Irritable Bowel Syndrome (IBS) Therapeutics

Figure Global Sales Market Share of I

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery